COVID Intel - by William Makis (McGill Medicine)

COVID Intel - by William Makis (McGill Medicine)

Creator
0 followers

INTEL on COVID-19, mRNA Vaccines, Turbo Cancer, Cancer Therapy, Ivermectin, Mebendazole, Fenbendazole. Content is for informational purposes only. Entirely donation based. None of the information constitutes medical advice (see your doctor as needed).

IVERMECTIN and FENBENDAZOLE Testimonial - 70 Year Old UK Woman with NHL B-Cell Lymphoma Reports After 5 Months - in...
BlogMay 8, 2026

IVERMECTIN and FENBENDAZOLE Testimonial - 70 Year Old UK Woman with NHL B-Cell Lymphoma Reports After 5 Months - in...

A 70‑year‑old woman in the United Kingdom diagnosed with B‑cell non‑Hodgkin lymphoma posted a personal testimonial claiming near remission after five months of self‑administered ivermectin and fenbendazole. The post attributes her improvement to the off‑label use of these antiparasitic drugs,...

By COVID Intel - by William Makis (McGill Medicine)
RESEARCH: NITAZOXANIDE in Head and Neck Squamous Cell Carcinoma - 2025 Paper From China
BlogMay 7, 2026

RESEARCH: NITAZOXANIDE in Head and Neck Squamous Cell Carcinoma - 2025 Paper From China

A 2025 Chinese study published in Springer Nature demonstrates that nitazoxanide, an FDA‑approved antiparasitic, exhibits potent anti‑tumor activity against head and neck squamous cell carcinoma (HNSCC). Using integrated single‑cell RNA sequencing and spatial transcriptomics, researchers identified that the drug down‑regulates...

By COVID Intel - by William Makis (McGill Medicine)
IVERMECTIN and MEBENDAZOLE Testimonial - 73 Year Old Massachusetts Man with 2 Liver Cancers and Liver Transplant Candidate Reports After...
BlogMay 5, 2026

IVERMECTIN and MEBENDAZOLE Testimonial - 73 Year Old Massachusetts Man with 2 Liver Cancers and Liver Transplant Candidate Reports After...

A 73‑year‑old man from Massachusetts diagnosed with two liver cancers claims that a ten‑month regimen of ivermectin and mebendazole has caused his tumors to shrink, positioning him as a candidate for a liver transplant. The testimonial, posted on a health‑focused...

By COVID Intel - by William Makis (McGill Medicine)
RESEARCH: HBOT in CANCER (Hyperbaric Oxygen Therapy) - 2025 Review Paper From Sichuan University, Chengdu, China
BlogMay 5, 2026

RESEARCH: HBOT in CANCER (Hyperbaric Oxygen Therapy) - 2025 Review Paper From Sichuan University, Chengdu, China

A 2025 review paper from Sichuan University evaluates hyperbaric oxygen therapy (HBOT) as an adjunct in cancer treatment. The authors synthesize pre‑clinical data showing HBOT reverses tumor hypoxia and enhances the potency of radiotherapy and certain chemotherapies. They also examine...

By COVID Intel - by William Makis (McGill Medicine)
IVERMECTIN, FENBENDAZOLE, HBOT Testimonial - 70 Year Old NEW ZEALAND Man with Stage 4 Pancreatic Cancer Given 2-3 Months to...
BlogMay 4, 2026

IVERMECTIN, FENBENDAZOLE, HBOT Testimonial - 70 Year Old NEW ZEALAND Man with Stage 4 Pancreatic Cancer Given 2-3 Months to...

A 70‑year‑old New Zealand man with stage 4 pancreatic cancer, originally given a 2‑3 month prognosis, claims to be cancer‑free after a year of self‑administered ivermectin, fenbendazole and hyperbaric oxygen therapy (HBOT) without conventional chemo or radiation. The testimonial, posted on a Substack...

By COVID Intel - by William Makis (McGill Medicine)
RESEARCH: NICLOSAMIDE in CANCER and Other Diseases - 2025 Review Paper From Henan, China
BlogMay 3, 2026

RESEARCH: NICLOSAMIDE in CANCER and Other Diseases - 2025 Review Paper From Henan, China

A 2025 review paper from Henan, China, evaluates niclosamide—a decades‑old anti‑parasitic—as a repurposed oncology agent. The analysis compiles pre‑clinical data across breast, lung, pancreatic and colorectal cancers, and highlights early‑phase clinical trials showing modest tumor responses. Researchers also discuss formulation...

By COVID Intel - by William Makis (McGill Medicine)
RESEARCH - Ivermectin and AUTOIMMUNITY - How Ivermectin Could Help Autoimmune Diseases - 2025 Paper by Iraqi Researchers
BlogApr 30, 2026

RESEARCH - Ivermectin and AUTOIMMUNITY - How Ivermectin Could Help Autoimmune Diseases - 2025 Paper by Iraqi Researchers

Iraqi researchers published a 2025 study proposing ivermectin as a potential therapeutic for autoimmune diseases. The paper outlines pre‑clinical data showing ivermectin modulates immune pathways, reducing inflammatory cytokine production in mouse models of lupus and rheumatoid arthritis. Researchers suggest repurposing...

By COVID Intel - by William Makis (McGill Medicine)
IVERMECTIN and FENBENDAZOLE Testimonial - 69 Year Old Utah Man with Prostate Cancer Reports After 1 Year: PSA Dropped From...
BlogApr 23, 2026

IVERMECTIN and FENBENDAZOLE Testimonial - 69 Year Old Utah Man with Prostate Cancer Reports After 1 Year: PSA Dropped From...

A 69‑year‑old Utah man with prostate cancer posted a year‑long testimonial claiming his PSA level fell from 8.2 to 2.1 after taking off‑label ivermectin and fenbendazole. The post frames the drop as a dramatic improvement, attributing it to the antiparasitic...

By COVID Intel - by William Makis (McGill Medicine)
IVERMECTIN and HERPES - 20 Quick Testimonials
BlogApr 11, 2026

IVERMECTIN and HERPES - 20 Quick Testimonials

An online blog post titled “Ivermectin and Herpes – 20 Quick Testimonials” compiles twenty personal accounts claiming the antiparasitic drug ivermectin alleviates herpes simplex outbreaks. The piece provides no clinical data, dosage information, or peer‑reviewed evidence to support the claims....

By COVID Intel - by William Makis (McGill Medicine)
IVERMECTIN, FENBENDAZOLE, MCP, CBD Testimonial - 63 Year Old Pennsylvania Man with Colon Cancer Reports After 10 Months - CANCER...
BlogApr 4, 2026

IVERMECTIN, FENBENDAZOLE, MCP, CBD Testimonial - 63 Year Old Pennsylvania Man with Colon Cancer Reports After 10 Months - CANCER...

A 63‑year‑old Pennsylvania man with colon cancer claims he has been cancer‑free for ten months after self‑administering a cocktail of ivermectin, fenbendazole, MCP and CBD. The testimonial, posted on a personal blog, highlights his belief that the off‑label regimen halted...

By COVID Intel - by William Makis (McGill Medicine)
CANCER RESEARCH - TOCOTRIENOLS - 2025 Review - Therapeutic Potential of Tocotrienols as Chemosensitizers in Cancer Therapy (Why They Are...
BlogMar 19, 2026

CANCER RESEARCH - TOCOTRIENOLS - 2025 Review - Therapeutic Potential of Tocotrienols as Chemosensitizers in Cancer Therapy (Why They Are...

The 2025 review examines tocotrienols, a subset of vitamin E, as chemosensitizers that boost the effectiveness of conventional cancer drugs. Pre‑clinical studies show that combining tocotrienols with antiparasitic agents such as fenbendazole or mebendazole markedly increases tumor cell death. The analysis...

By COVID Intel - by William Makis (McGill Medicine)
COVID Intel - by William Makis (McGill Medicine) | Pulse